

April 29–30, 2014 • Marriott Bethesda North Hotel & Conference Center • Bethesda, MD (Washington, DC)

# Drug and Device Recalls Summit

Product recalls are on the rise — devices saw a 28% increase in 2013 compared to 2012, and drugs followed with a 17% increase. Some industry observers have called it a “crisis.”

Today, it's vitally necessary that manufacturers have a proactive recall strategy that will work effectively in the United States and other every country where your products are sold.

This conference will provide you with what you must know NOW about recall readiness — real-life lessons, invaluable tips and proven techniques to take back to your company and deploy at once.

## Conference Speakers

- **Heath Rushing**  
Principal Consultant Adsurgo LLC
- **Julianne McCullough**  
Recall Coordinator, Philadelphia District Office, ORA, FDA (invited)
- **Kevin Morrow**  
Recall Coordinator, Baltimore District Office, ORA, FDA (invited)
- **Ronny Brown**  
Chief, Recall Branch, Division of Risk Management Operations, Office of Compliance, CDRH, FDA (invited)
- **Marialuisa (“ML”) Gallozzi**  
Partner, Covington & Burling
- **Suzan Charlton**  
Special Counsel, Covington & Burling
- **James Johnson**  
Associate, Hogan Lovells; former Associate Chief Counsel in the FDA’s Office of the Chief Counsel
- **Sunni Churchill**  
Senior Director, Regulatory Affairs, US Generics, Teva Pharmaceuticals
- **Joe Falvo**  
Senior Manager: Post Market Risk Management, Ortho Clinical Diagnostics
- **Rita Hoffman**  
Principal Consultant, Regs & Recall Strategies, LLC; former Branch Chief, Recalls, CDRH, FDA
- **Todd Halpern**  
Assistant General Counsel, Regulatory Law, Pfizer

Visit [www.RecallsSummit.com](http://www.RecallsSummit.com) or call (888) 838-5578

**FDANEWS**

## PRE-CONFERENCE WORKSHOP – TUESDAY, APRIL 29, 2014

**8:30 a.m. – 9:00 a.m.**

**Registration and Continental Breakfast**

**9:00 p.m. – 12:00 p.m.**

**Harness the Power of Text Mining – Using the FDA’s Recall Data to Identify and Isolate Root Causes of Nonconformances**

Nonconformance reports are written by different people in different areas of your business. That’s why they often use different words or ideas to report the same problem. The solution? By developing a word matrix that scours FDA data and ranks pre-determined words based on importance and frequency, drug and device companies can now translate various nonconformance reports into a “word cloud” that very often shows what the true root problem is for a nonconformance. One medical device company conducted this exercise and found the words “ventilator,” “infusion” and “simulator,” which led them to quickly determine what their true root problems were in relation to nonconformance.

During this workshop, the instructor will teach attendees, using live FDA data, how text mining can help them analyze FDA data and determine how their products and other products in their class are being reported and if there are trends that show potential problems they may not anticipate.

Attendees will learn:

- How a medical device company was able to analyze its various nonconformance reports and narrow its root causes down to three words: infusion, ventilator and simulator.
- How to develop and populate a tracking matrix to collect the raw data needed for text mining.
- Proven tools and tactics to perform text analytics to decipher that data.

**Heath Rushing, Principal Consultant Adsurgo, LLC**

## AGENDA

**Plenary DAY ONE  
Tuesday, April 29, 2014**

**12:00 p.m. – 1:00 p.m.**

**Registration and Lunch**

**1:00 p.m. – 1:15 p.m.**

**Opening Comments by Chairperson**

**David Elder, Vice President of Strategic Compliance Services, PAREXEL Consulting; former Director of the Office of Enforcement, ORA, FDA**

**1:15 p.m. – 2:15 p.m.**

**FDA’s Recall Root Cause Research Project**

Lessons from the past can protect against the disaster of tomorrow. Data and information collected by the FDA’s Recall Root Cause Research project is being analyzed to illuminate the root causes of recalls within the bio/ pharmaceutical industry. By learning from these examples, pharma companies can minimize defects and failures leading to recalls and thus improve patient safety. This session reviews the goals and objectives of the project and gives an update on key findings to this point.

Attendees will learn:

- The most common and simple mistakes FDA observes in recall programs.
- Five simple tips to make a quick assessment of your own program.
- What specific kinds of information you can supply FDA to make your recall run more smoothly.
- The key differences between effective drug and device recall programs.

**2:15 p.m. – 3:00 p.m.**

**How to Recover the Costs of a Recall**

Drug and device companies correctly put patient and consumer safety first when dealing with product recalls. In this presentation, the speakers will delve into how companies can recapture the financial and reputational cost of a recall. Insurance can provide coverage for many of the costs of a recall, potentially including direct losses of product and indirect losses from business interruption, loss of market share and sometimes even brand rehabilitation. Plus, various unique insurance policies help with product liability, directors’ and officers’ liability, and errors and omissions.

Attendees will learn:

- How and why to measure and document the financial and other costs of a recall.
- How to purchase insurance coverage for

recall-related losses and liabilities and recover from insurance when a recall happens.

- What lessons prior recalls teach about financial risk management and cost-capture planning, before a recall happens.

**3:00 p.m. – 3:15 p.m.**

**Refreshment Break**

**3:15 p.m. – 4:45 p.m.**

**Panel Discussion: How to Master International Recalls**

As supply and demand requirements become more and more international, it has never been more important to drug and device firms to understand the unique requirements of a global recall. Regulatory requirements and attitudes can vary from country to country just as much as their cultures can vary from national to nation, region to region, and even among individual regulatory officials. It’s not easy to understand all of those nuances; unfortunately, learning them isn’t optional for any company operating outside the United States. This panel will probe these and other considerations when developing and executing a global recall.

Attendees will:

- Understand the different regulatory expectations in dozens of foreign markets.
- Build processes that address both

domestic and global recalls.

- Understand best practices for working to strengthen the global supply chain.

**4:45 p.m. – 6:00 p.m.**

## Networking Reception

### Tracks and Plenary Closing Session DAY TWO Wednesday, April 30, 2014

**8:00 a.m. – 8:45 a.m.**

## Continental Breakfast

**8:45 a.m. – 3:00 p.m.**

## Two Concurrent Breakout Tracks

### Track 1 — Drugs and Biologics

### Track 2 — Medical Devices and Diagnostics

#### Drugs and Biologics Track

**8:45 a.m. – 9:00 a.m.**

## Track Chairperson Comments

**9:00 a.m. – 10:00 a.m.**

## Pharmaceutical and Biologics Recall 2014 Update

The number of drug recalls shot up 17 percent in 2013 compared to 2012, buoyed by a spate of generic injectable drug recalls. There were 341 pharmaceutical recall events in 2013, up from 291 in 2012. In 2013, the FDA published 21 recall notices due to a lack of sterility assurance, far above the seven in 2012. Foreign particles in drug products were another key quality problem of concern last year, accounting for 19 recall notices, compared with 12 in 2012. In this session, you'll get a look at how the FDA classified recalls in 2014 and what triggering events were keys in high profile recalls.

**10:00 a.m. – 10:45 a.m.**

## Lessons Learned in the Aftermath of Notable OTC Recalls: Understanding the Consequences and Corrective Actions

Drawing on the best practices — and biggest mistakes — that have come out of several illustrative recalls, this session offers attendees a front-row seat in the dissection of an effective Corrective and Preventative Action program. What worked? What didn't? Which are the models to emulate — and what are the disasters you need to learn from and avoid? This session will deliver the invaluable perspective of the former Associate Chief Counsel in the FDA's Office of Chief Counsel.

Attendees will learn about:

- Examining recall activity relating to OTC products from 2009 to present.

- Evaluating the risks and benefits of cooperating with the FDA in the course of a recall.
- The FDA's recall and oversight authority with respect to OTC and other drug products.
- The FDA's recall expectations for prescription drugs vs. OTC products.
- Recall requirements under the Consumer Product Safety Act.
- The implications of voluntary recalls versus mandatory recalls.
- Best practices for managing market withdrawals and stock recoveries.
- The consequences of not instituting a recall.
- The FDA's latest posture on using its seizure and injunction powers.
- Tips for assuring building procedures to link your recall strategy to corrective and preventive action strategy.
- Proven strategies for introducing a product back to market.
- Examples of recent successful product reintroductions.

**10:45 a.m. – 11:00 a.m.**

## Refreshment Break

**11:00 a.m. – 11:45 a.m.**

## The Role of Regulatory Affairs in Recall Management and Drug Shortage Notification

Regulatory affairs has both an important internal and external role. When a recall hits, regulatory affairs should be an early responder working with the FDA and internal departments. In October 2013, the FDA announced its Strategic Plan for Preventing and Mitigating Drug Shortages. The plan's goals include early and open dialogue between the FDA and manufacturers regarding recalls and other manufacturing related shortages. Walk step-by-step alongside a drug industry regulatory affairs expert to learn to how recalls can require prompt communication with the FDA as required by the Strategic Plan for Preventing and Mitigating Drug Shortages.

Attendees will learn:

- How regulatory affairs best function both internally and externally from the outset of a possible recall.
- Manufacturer's responsibilities regarding notification under the FDA's Strategic Plan for Preventing and Mitigating Drug Shortages.
- Best practices for getting and keeping regulatory affairs and quality affairs on the same page during recalls.

**11:45 a.m. – 12:30 p.m.**

## Improving Your Recall Execution Process

It all comes down to proper planning and your recall process. Understanding the distribution process and the specifics of how a product gets to market will help with a more effective collaboration and communication in a recall situation. Each stakeholder should have a comprehensive understanding of the interworkings of the process and how they can best work together to accomplish the desired results.

Attendees will learn:

- How to identify the key stakeholders within your supply chain; wholesalers, distributors, hospitals, pharmacies.
- What unique role each plays in a recall situation — and what your responsibilities to each are.
- Best practices for communicating to stakeholder group to accomplish a successful recall.

**12:30 p.m. – 1:30 p.m.**

## Lunch

**1:30 p.m. – 3:00 p.m.**

## Panel Discussion: Impact Analysis of Recalls — Keys to a Positive Outcome

It is important to focus on the standard of compliance during a recall situation. But that shouldn't be your only focus. Many companies lose sight of the end impact a recall can have on a company. This session will discuss processes and techniques that can be implemented in your company to help achieve a positive outcome.

Attendees will learn:

- Ways to improve the economic impact of recall
- Techniques for a positive result from a recall situation

#### Medical Device and Diagnostics Track

**8:45 a.m. – 9:00 a.m.**

## Track Chairperson Comments

**9:00 a.m. – 10:00 a.m.**

## Medical Device Recall 2014 Update

In this session, you'll get an inside look at how the FDA classifies recalls and what triggering events suggest a potential recall. Learn how field service corrections can become recalls and how using prior information can facilitate earlier vigilance, outreach and action.

## 10:00 a.m. – 10:45 a.m. Recall Process Lifecycle – SOPs, Preparation and Effective Execution

If you do not experience many recalls, or have not experienced any in the past couple years, keeping your process up-to-date can suffer. Understanding and constantly maintaining recall readiness vigilance is imperative as you now know when a recall might be necessary. This session will demonstrate how to integrate best practices throughout your organization that will maintain your recall readiness.

Attendees will learn:

- How to assure staff understands recall SOPs so they are prepared for the day a recall occurs.
- How mock recall audits help staff to know their roles and be prepared.
- Best practices for putting SOPs into action once a recall is initiated.

## 10:45 a.m. – 11:00 a.m. Refreshment Break

## 11:00 a.m. – 11:45 a.m. Secrets of Successful Recall Termination Procedures

Once all reasonable efforts have been made to remove or correct the product, now the termination process can begin. The final step is just as important as the first. It is necessary to maintain a functional supply chain and continue to foster the relationships with the key stakeholders.

Attendees will learn:

- Crucial timing for the recall termination.
- Importance of keeping in communication with the District Office.
- How to execute a formal recall closeout.

## 11:45 a.m. – 12:30 p.m. Risk Evaluation and Techniques that Meet FDA Standards

Recent trends in recalls suggest the FDA is more demanding of a company's analysis of potential health risk associated with the recalled product. The FDA is looking closely at the classification of recalls based on health risk. Companies must be confident that their health risk analysis dovetails with the FDA's use of risk tools such as Health Hazard Evaluation (HHE). It is crucial that companies understand the FDA's health risk analysis, including its recall classification and potential direct public outreach to physicians, patients and consumers.

Attendees will learn:

- How to align your internal health risk assessment with the FDA's HHE process.
- Common misalignments between industry and FDA health risk analyses.
- The reporting obligations related to health risk.
- How to prepare your company for the agency's potential public communications about your product.

## 12:30 p.m. – 1:30 p.m. Lunch

## 1:30 p.m. – 3:00 p.m. Panel Discussion: Field Corrections vs. Silent Recalls vs. Enhancements

Many firms are issuing field corrections and product removal announcements without ever notifying the FDA. CDRH's Office of Compliance has said the agency is on the lookout for these "silent recalls," noting that something as simple as sending out a patch to fix a software glitch can rise to the level of a reportable event. Where you draw the line between a routine servicing issue and a malfunction repair can be complicated. Firms that understand the reporting requirements can avoid taking an already expensive problem and turning it into a regulatory mess. A February 22 FDA guidance suggests that device modifications that enhance the quality, safety or effectiveness of a product — such as improvements in design — won't necessarily trigger a recall of supplies in the field. Understanding the nuances of terms such as correction and enhancement and how you manage them is paramount for devicemakers.

Attendees will learn:

- What types of events must be reported, what are the deadlines and how to document your actions.
- Understanding what constitutes an enhancement and how to apply the Feb. 22 guidance.

## 3:00 p.m. – 3:15 p.m. Refreshment Break

## PLENARY SESSION PANEL DISCUSSION

## 3:15 p.m. – 4:00 p.m. Lessons from the Front Lines: Understanding How to Build Effective Internal Recall Committees

Walk through the step-by-step process for developing and implementing stress-tested

Internal Recall Committees with a leading industry expert and long-time professional.

Attendees will learn:

- How to design an efficient process and cross-functional team.
- Best practices for communicating with regulators, healthcare professionals and other key stakeholders.
- How to handle potential product liability and other complex legal issues implicated by a recall.

## 4:00 p.m. – 5:00 p.m. Panel Discussion: Recall Trends — Finding the Root Cause

The number of drug recalls shot up 17 percent in 2013 compared to 2012, buoyed by a spate of generic injectable drug recalls. There were 341 pharmaceutical recall events in 2013, up from 291 in 2012. In 2013, the FDA published 21 recall notices due to a lack of sterility assurance, far above the seven in 2012. Foreign particles in drug products were another key quality problem of concern last year, accounting for 19 recall notices, compared with 12 in 2012. Device recalls also have been on the rise, the report shows. In 2007, the number of CDRH recalls was 1,279, and that figure climbed to 3,211 in 2011. Of those, 16 percent were due to process controls, 14 percent to design flaws and 12 percent to software design concerns. This panel discussion will examine multiple recalls and discuss how the root cause was determined and how the company and the FDA determined that effective CAPAs were put in place to allow for continued production.

Attendees will learn:

- What recall examples of recent years teach us about how to conduct better root cause investigations.
- How arriving at comprehensive root cause determinations can positively impact future manufacturing improvements.
- What the FDA wants to see in CAPAs related to recalled products so products can safely be put back on the market.

## 5:00 p.m. – 5:15 p.m. Closing Comments by Chairperson

## 5:15 p.m. Conference Concludes

# Drug and Device Recalls Summit

April 29–30, 2014 • Marriott Bethesda North Hotel & Conference Center • Bethesda, MD (Washington, DC)

## ABOUT YOUR CHAIRMAN



### **David Elder, Vice President of Strategic Compliance Services, PAREXEL Consulting**

David Elder is Vice President of Strategic Compliance Services at PAREXEL Consulting. Mr. Elder served as the Director of the Office of Regional Operations (ORO) within the Office of Regulatory Affairs (ORA) where he managed a team of professionals working around the globe to ensure that regulated products met the FDA's standards, rules and regulations. Previously, Mr. Elder was Director of the Office of Enforcement within ORA. Prior to this position, he served in the FDA's New England District Office as an investigator, compliance officer, and as Director of the Compliance Branch. During his 23 year tenure with the FDA, Mr. Elder was involved in domestic and foreign inspections, recalls and emergencies, and compliance actions involving hundreds of situations. He testified in federal court and before Congress, initiated and approved enforcement actions, and represented the FDA during national media events. As Office Director for both Enforcement and Regional Operations, he was a principal advisor to the Associate Commissioner of Regulatory Affairs at the FDA.

## WHO SHOULD ATTEND

- Quality assurance/Quality control
- Regulatory affairs
- Legal and compliance officers
- Executive management
- Risk management specialists
- Operations and manufacturing professionals
- General/corporate counsel
- Media and public relations professionals
- Medical affairs

## SPONSORS

### Gold Sponsor

# PAREXEL®

PAREXEL Consulting is your strategic guide in the product development journey with scientific, regulatory, and commercial expertise that put best practice standards to work, designing solutions for the complexities of an ever-changing global marketplace.

Our experienced team of former FDA investigators and quality professionals proactively minimize risk and effectively respond to urgent compliance challenges with an approach that is grounded in the belief that compliance and quality should be managed as any other critical business issue. Proper quality management and a state of regulatory compliance will result in a decrease in direct costs such as rejects, and indirect costs such as adverse events and recalls. From loaned executives to global audits, ad-hoc advice or inspection readiness training, we help manage risk effectively in global markets to protect and grow product and company reputation and value.

Exhibit and sponsorship opportunities are still available.

Contact Jim Desborough

Phone: +1 (703) 538-7642

Email: [jdesborough@fdanews.com](mailto:jdesborough@fdanews.com)

# Drug and Device Recalls Summit

April 29–30, 2014 • Marriott Bethesda North Hotel & Conference Center • Bethesda, MD (Washington, DC)

## LOCATION AND HOTEL ACCOMODATIONS

To reserve your room, call the hotel at the number below. Be sure to tell the hotel you're with the **FDAnews Conference** to qualify for the reduced rate. Only reservations made by the reservation cutoff date are offered the special rates, and space is limited. Hotels may run out of discounted rates before the reservation cutoff date. The discounted rate is also available two nights before and after the event based on availability. Hotel may require first night's room deposit with tax. Room cancellations within 72 hours of the date of arrival or "no-shows" will be charged for the first night's room with tax.

## LODGING AND CONFERENCE VENUE:

April 29-30, 2014  
 Bethesda North Marriott Hotel & Conference Center  
 5701 Marinelli Road  
 North Bethesda, MD 20852  
 Toll free: (800) 859-8003 • Tel: +1 (301) 822-9200  
 www.bethesdanorthmarriott.com  
 Room rate: \$199.00 plus 13 percent tax  
 Reservation cut-off date: Apr. 7, 2014

## TUITION

Complete conference includes all sessions, materials, two breakfasts, two luncheons and daily refreshments.

## CANCELLATIONS AND SUBSTITUTIONS

Written cancellations received at least 21 calendar days prior to the start date of the event will receive a refund – less a \$200 administration fee. **No cancellations will be accepted – nor refunds issued – within 21 calendar days from the start date of the event.** A credit for the amount paid may be transferred to any future FDAnews event. Substitutions may be made at any time. No-shows will be charged the full amount. In the event that FDAnews cancels the event, FDAnews is not responsible for any airfare, hotel, other costs or losses incurred by registrants. Some topics and speakers may be subject to change without notice.

## TEAM DISCOUNTS

Significant tuition discounts are available for teams of two or more from the same company. You must register at the same time and provide a single payment to take advantage of the discount. Call +1 (703) 538-7600 for details.

## FOUR EASY WAYS TO REGISTER

- Online:** www.RecallsSummit.com
- Fax:** +1 (703) 538-7676
- Phone:** Toll free (888) 838-5578 (inside the U.S.)  
or +1 (703) 538-7600
- Mail:** FDAnews, 300 N. Washington St., Suite 200  
Falls Church, VA 22046-3431 USA

**YES!** I want to attend *Drug and Device Recalls Summit* on April 29–30, 2014 in Bethesda, MD

# FDANEWS

300 N. Washington St., Suite 200  
 Falls Church, VA 22046-3431

	Early Bird Fee until April 1, 2014	No. of Attendees	Regular Fee April 2–30, 2014	No. of Attendees
Complete Summit	\$1597		\$1797	
Conference Only	\$1327		\$1497	
Preconference Workshop Only	\$397		\$497	

Attendee 1: Name \_\_\_\_\_ Title \_\_\_\_\_ Email \_\_\_\_\_

Attendee 2: Name \_\_\_\_\_ Title \_\_\_\_\_ Email \_\_\_\_\_

Email address (so you can receive order acknowledgements, updated news, product information and special offers)

### Company Information

Organization \_\_\_\_\_  
 Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
 Country \_\_\_\_\_  
 Phone \_\_\_\_\_ Fax \_\_\_\_\_

### Payment Options

- Check enclosed, payable in U.S. funds to FDAnews
- Charge to:  Visa  MasterCard  American Express

Credit card no. \_\_\_\_\_  
 Expiration date \_\_\_\_\_  
 Total amount \$ \_\_\_\_\_  
 Signature \_\_\_\_\_

(Signature required on credit card and bill-me orders)

Print name \_\_\_\_\_

Bill me/my company \$ \_\_\_\_\_

Purchase order # \_\_\_\_\_

(Payment is required by the date of the conference.)